These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12011054)

  • 1. Disabling receptor ensembles with rationally designed interface peptidomimetics.
    Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
    J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
    Garrett TP; McKern NM; Lou M; Elleman TC; Adams TE; Lovrecz GO; Kofler M; Jorissen RN; Nice EC; Burgess AW; Ward CW
    Mol Cell; 2003 Feb; 11(2):495-505. PubMed ID: 12620236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
    Mendrola JM; Berger MB; King MC; Lemmon MA
    J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
    Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
    Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bacterial synthesis, purification, and solubilization of transmembrane segments of ErbB family members].
    Goncharuk MV; Shul'ga AA; Ermoliuk IaS; Tkach EN; Goncharuk SA; Pustovalova IuE; Mineev KS; Bocharov ÉV; Maslennikov IV; Arsen'ev AS; Kirpichnikov MP
    Mol Biol (Mosk); 2011; 45(5):892-902. PubMed ID: 22393787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
    Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
    J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo.
    Xu R; Povlsen GK; Soroka V; Bock E; Berezin V
    Cell Oncol; 2010 Jan; 32(4):259-74. PubMed ID: 20364069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
    van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
    J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
    Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
    Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells.
    Hiroshima M; Saeki Y; Okada-Hatakeyama M; Sako Y
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):13984-9. PubMed ID: 22891299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.
    Franco-Gonzalez JF; Ramos J; Cruz VL; Martínez-Salazar J
    J Mol Model; 2013 Feb; 19(2):931-41. PubMed ID: 23090500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study.
    Motamedi Z; Rajabi-Maham H; Azimzadeh Irani M
    J Mol Model; 2021 Nov; 27(12):361. PubMed ID: 34817689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
    Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
    Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells.
    Staberg M; Riemer C; Xu R; Dmytriyeva O; Bock E; Berezin V
    Cell Oncol (Dordr); 2013 Jun; 36(3):201-11. PubMed ID: 23580313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.
    Hart MR; Su HY; Broka D; Goverdhan A; Schroeder JA
    Mol Ther; 2013 Nov; 21(11):1996-2007. PubMed ID: 24081029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
    Banappagari S; Corti M; Pincus S; Satyanarayanajois S
    J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.